arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CRISPR Therapeutics AG

CRSP
$53.51 ▲ +1.90 (+3.68%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
45 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CRISPR Therapeutics AG faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.1B
Dividend Yield
Revenue Growth 68.6%
Op. Margin None
ROIC -5.5%
FCF / Share $-1.14
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity 0.32
info Valuation on last close. End-of-day price, Aug 7, 2026.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.46M
↑ +68.6%
Net Income Profit after all expenses
$-122.93M
↑ +9.6%
Operating Margin Operating profit as % of sales
-181.0%
↓ -623.3%
FCF / Share Free cash flow per share
$-1.14
↓ -80.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
23
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 45 quarters